Maria Paula do Amaral Alegria Guedes de Pinho

senior researcher

Research Group
Coordinator Researcher (Permanent contract) (since 2023)
Personal Website
Phone number
220428000 (8796)
Ciência Vitae

Recent publications

  • Lima, AR; Carvalho, M; Aveiro, SS; Melo, T; Domingues, MR; Macedo-Silva, C; Coimbra, N; Jeronimo, C; Henrique, R; Bastos, MD; de Pinho, PG; Pinto, J. 2022. Comprehensive Metabolomics and Lipidomics Profiling of Prostate Cancer Tissue Reveals Metabolic Dysregulations Associated with Disease Development. JOURNAL OF PROTEOME RESEARCH, 21, DOI: 10.1021/acs.jproteome.1c00754
  • Dionisio, F; Araujo, AM; Duarte-Araujo, M; Bastos, MD; de Pinho, PG; Carvalho, F; Costa, VM. 2022. Cardiotoxicity of cyclophosphamide's metabolites: an in vitro metabolomics approach in AC16 human cardiomyocytes. ARCHIVES OF TOXICOLOGY, DOI: 10.1007/s00204-021-03204-y
  • Pinto, J; Amaro, F; Lima, AR; Carvalho-Maia, C; Jeronimo, C; Henrique, R; Bastos, MD; Carvalho, M; de Pinho, PG. 2021. Urinary Volatilomics Unveils a Candidate Biomarker Panel for Noninvasive Detection of Clear Cell Renal Cell Carcinoma. JOURNAL OF PROTEOME RESEARCH, 20, DOI: 10.1021/acs.jproteome.0c00936
  • Lima, AR; Pinto, J; Amaro, F; Bastos, MD; Carvalho, M; de Pinho, PG. 2021. Advances and Perspectives in Prostate Cancer Biomarker Discovery in the Last 5 Years through Tissue and Urine Metabolomics. Metabolites, 11, DOI: 10.3390/metabo11030181
  • Pinto, J; Carapito, A; Amaro, F; Lima, AR; Carvalho-Maia, C; Martins, MC; Jeronimo, C; Henrique, R; Bastos, MD; de Pinho, PG. 2021. Discovery of Volatile Biomarkers for Bladder Cancer Detection and Staging through Urine Metabolomics. Metabolites, 11, DOI: 10.3390/metabo11040199
  • Ana Rita Lima; Joana Pinto; Daniela Barros-Silva; Carmen Jerónimo; Rui Henrique; Maria de Lourdes Bastos; Márcia Carvalho; Paula Guedes Pinho. 2020. New findings on urinary prostate cancer metabolome through combined GC–MS and 1H NMR analytical platforms. Metabolomics, 16(6), DOI: 10.1007/s11306-020-01691-1
  • Ara?jo, AM; Carvalho, M; Bastos, MD; Carvalho, F; de Pinho, PG. 2019. Metabolic signature of methylone in primary mouse hepatocytes, at subtoxic concentrations. ARCHIVES OF TOXICOLOGY, 93, DOI: 10.1007/s00204-019-02566-8
  • Araujo, AM; Bastos, MD; Fernandes, E; Carvalho, F; Carvalho, M; de Pinho, PG. 2018. GC-MS metabolomics reveals disturbed metabolic pathways in primary mouse hepatocytes exposed to subtoxic levels of 3,4-methylenedioxymethamphetamine (MDMA). ARCHIVES OF TOXICOLOGY, 92, DOI: 10.1007/s00204-018-2314-9
  • Lima, AR; Araujo, AM; Pinto, J; Jeronimo, C; Henrique, R; Bastos, MD; Carvalho, M; de Pinho, PG. 2018. Discrimination between the human prostate normal and cancer cell exometabolome by GC-MS. Scientific Reports, 8, DOI: 10.1038/s41598-018-23847-9
  • Araujo, AM; Carvalho, M; Carvalho, F; Bastos, MD; de Pinho, PG. 2017. Metabolomic approaches in the discovery of potential urinary biomarkers of drug-induced liver injury (DILI). CRITICAL REVIEWS IN TOXICOLOGY, 47, DOI: 10.1080/10408444.2017.1309638
  • Monteiro, M; Moreira, N; Pinto, J; Pires-Luis, AS; Henrique, R; Jeronimo, C; Bastos, MD; Gil, AM; Carvalho, M; de Pinho, PG. 2017. GC-MS metabolomics-based approach for the identification of a potential VOC-biomarker panel in the urine of renal cell carcinoma patients. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 21, DOI: 10.1111/jcmm.13132
  • Calejo, I; Moreira, N; Araujo, AM; Carvalho, M; Bastos, MD; de Pinho, PG. 2016. Optimisation and validation of a HS-SPME-GC-IT/MS method for analysis of carbonyl volatile compounds as biomarkers in human urine: Application in a pilot study to discriminate individuals with smoking habits. TALANTA, 148, DOI: 10.1016/j.talanta.2015.09.070
  • Lima, AR; Bastos, MD; Carvalho, M; de Pinho, PG. 2016. Biomarker Discovery in Human Prostate Cancer: an Update in Metabolomics Studies. Translational Oncology, 9, DOI: 10.1016/j.tranon.2016.05.004

Main research interests

  • 1. Development of GC-MS methodologies to determine low molecular weight compounds in different biological matrices: in vitro and ex vivo cellular systems, plasma and urine.
  • 2. Studies of “legal” drugs of abuse toxicity by using in vitro and in vivo models.
  • 3. Use of Metabolomics to prostate, bladder and renal cell carcinoma Detection and Biomarker Discovery.
  • 4. Use metabolomic to dissect mechanisms of action and to find new and sensitive biomarkers of toxicity (Toxicometabolomics).